GlaxoSmithKline Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹2,344.55(-2.02%)January 16, 2026 15:20:23 PM IST
- NSE
- BSE
- Vol : 61.57 K (NSE + BSE)Last 20 day avg : 88.55 K
GlaxoSmithKline Pharmaceuticals is trading -2.02% lower at Rs 2,344.55 as compared to its last closing price. GlaxoSmithKline Pharmaceuticals has been trading in the price range of 2,394.50 & 2,343.70. GlaxoSmithKline Pharmaceuticals has given -3.19% in this year & -2.64% in the last 5 days. GlaxoSmithKline Pharmaceuticals has TTM P/E ratio 47.17 as compared to the sector P/E of 22.69.There are 4 analysts who have initiated coverage on GlaxoSmithKline Pharmaceuticals. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 257.49 Crores in its last quarter.Listed peers of GlaxoSmithKline Pharmaceuticals include Dr Reddy's Laboratories (-0.91%), Sun Pharmaceutical Industries (-1.84%), Divi's Laboratories (-1.93%).The Mutual Fund holding in GlaxoSmithKline Pharmaceuticals was at 4.77% in 31 Dec 2025. The MF holding has decreased from the last quarter. The FII holding in GlaxoSmithKline Pharmaceuticals was at 4.63% in 31 Dec 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jan 16, 2026, 11:16 PM UTC
- BetaLow volatility0.25Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldHigher than industry1.75Annual dividends as a percentage of the stock price.
- P/BHigher than historical values20.79The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values42.47Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.23The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Dr Reddy's Laboratories | Bearish | 1,175.65 | -0.91 | 98,110.38 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | Bearish | 1,669.20 | -1.84 | 4,00,487.56 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | Bearish | 6,233.95 | -1.93 | 1,65,491.79 | 78.61 | 11.52 | 0.46 | 0.01 |
| Torrent Pharmaceuticals | Bullish | 4,018.75 | 0.35 | 1,36,007.30 | 67.32 | 17.1 | 0.83 | 17.62 |
| Cipla | Bearish | 1,398.45 | -2.52 | 1,12,922.46 | 22.95 | 3.87 | 0.87 | 0.81 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-02-09 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-08-01 | Quarterly Results |
| 2025-05-13 | Audited Results & Final Dividend |
| 2025-02-14 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE159A01016
- BSE Code500660
- NSE CodeGLAXO
GlaxoSmithKline Pharmaceuticals is trading at 2344.55 as on Fri Jan 16 2026 09:50:23. This is -2.02% lower as compared to its previous closing price of 2392.95.
The market capitalization of GlaxoSmithKline Pharmaceuticals is 39788.40 Cr as on Fri Jan 16 2026 09:50:23.
The average broker rating on GlaxoSmithKline Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 2 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for GlaxoSmithKline Pharmaceuticals is 3515.95 whereas the 52 wk low is 1924.30
GlaxoSmithKline Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 47.17
- Sector P/E: 22.69
- Dividend Yield: 1.75%
- D/E ratio: 0.02
GlaxoSmithKline Pharmaceuticals reported a net profit of 927.58 Cr in 2025.
The Mutual Fund Shareholding was 4.77% at the end of 31 Dec 2025.
EQUITY QUICK LINKS
GlaxoSmithKline Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.